CDK4 and metastatic neoplasm: In a cohort study of 506 patients with hormone receptor–positive, ERBB2–negative metastatic breast cancer that progressed during endocrine therapy and CDK4/6i agents, younger age, de novo metastatic disease, and visceral involvement were independent factors associated with shorter progression-free survival.